Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Companies / Paragon Biosciences
Entity

Paragon Biosciences

Tracked across 1 events · 8 articles · First seen Apr 03, 2026 · Last active Jun 10, 2026

Sentiment
50
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 50
Business
Teva acquires Emalex Biosciences for ecopipam
Sun Pharma announced the closing of its acquisition of Emalex Biosciences, a private company created by Paragon Biosciences. The acquisition, valued at $700 million upfront with potential for an additional $200 million in milestone payments…
Impact: Paragon Biosciences created and supported Emalex Biosciences in advancing Ecopipam through clinical development. The acquisition of Emalex Biosciences by Sun Pharma represents a successful outcome for Paragon Biosciences' investment.
Jun 10, 2026 · 8 articles
NEWSDESK
Track Paragon Biosciences live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.